Aaron M Beedle

List of Publications by Year
in descending order

45 papers	2,107 citations	257450 24 h-index	265206 42 g-index
46 all docs	46 docs citations	46 times ranked	2555 citing authors

#	Article	IF	Citations
1	Sarcospan increases laminin-binding capacity of Î±-dystroglycan to ameliorate DMD independent of Galgt2. Human Molecular Genetics, 2022, 31, 718-732.	2.9	6
2	Mitochondrial dysfunction in skeletal muscle of fukutinâ€deficient mice is resistant to exerciseâ€and 5â€aminoimidazoleâ€4â€carboxamide ribonucleotideâ€induced rescue. Experimental Physiology, 2020, 105, 1767-1777.	2.0	4
3	Adult stem cell deficits drive Slc29a3 disorders in mice. Nature Communications, 2019, 10, 2943.	12.8	32
4	Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy. JCI Insight, 2019, 4, .	5.0	18
5	Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit EGFR activation. Bioorganic and Medicinal Chemistry, 2018, 26, 1167-1173.	3.0	14
6	Aggregate mesenchymal stem cell delivery ameliorates the regenerative niche for muscle repair. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1867-1876.	2.7	11
7	Defective mucin-type glycosylation on Î±-dystroglycan in COG-deficient cells increases its susceptibility to bacterial proteases. Journal of Biological Chemistry, 2018, 293, 14534-14544.	3.4	3
8	Transient HIF2A inhibition promotes satellite cell proliferation and muscle regeneration. Journal of Clinical Investigation, 2018, 128, 2339-2355.	8.2	52
9	AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression. Human Molecular Genetics, 2017, 26, 1952-1965.	2.9	35
10	Abnormal Skeletal Muscle Regeneration plus Mild Alterations in Mature Fiber Type Specification in Fktn-Deficient Dystroglycanopathy Muscular Dystrophy Mice. PLoS ONE, 2016, 11, e0147049.	2.5	9
11	377. AAV-Mediated Transfer of FKRP Shows Therapeutic Efficacy in a Murine Model of Limb-Girdle Muscular Dystrophy Type 2i, but Requires Tight Control of Gene Expression. Molecular Therapy, 2016, 24, S150.	8.2	0
12	LARGE2-dependent glycosylation confers laminin-binding ability on proteoglycans. Glycobiology, 2016, 26, 1284-1296.	2.5	17
13	Mitochondrial maintenance via autophagy contributes to functional skeletal muscle regeneration and remodeling. American Journal of Physiology - Cell Physiology, 2016, 311, C190-C200.	4.6	61
14	Lysosomal solute carrier transporters gain momentum in research. Clinical Pharmacology and Therapeutics, 2016, 100, 431-436.	4.7	37
15	Cryosectioning of Contiguous Regions of a Single Mouse Skeletal Muscle for Gene Expression and Histological Analyses. Journal of Visualized Experiments, 2016, , .	0.3	4
16	Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy. Skeletal Muscle, 2016, 6, 20.	4.2	20
17	Distribution of myosin heavy chain isoforms in muscular dystrophy: insights into disease pathology. Musculoskeletal Regeneration, 2016, 2, .	0.0	4
18	Inhibiting EGFR Dimerization Using Triazolyl-Bridged Dimerization Arm Mimics. PLoS ONE, 2015, 10, e0118796.	2.5	31

#	Article	IF	Citations
19	Design of a selenylsulfide-bridged EGFR dimerization arm mimic. Bioorganic and Medicinal Chemistry, 2015, 23, 2761-2766.	3.0	10
20	Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells. Cancer Letters, 2015, 369, 175-183.	7.2	24
21	Lysophosphatidic Acid Mediates Activating Transcription Factor 3 Expression Which Is a Target for Post-Transcriptional Silencing by miR-30c-2-3p. PLoS ONE, 2015, 10, e0139489.	2.5	3
22	Development of Rabbit Monoclonal Antibodies for Detection of Alpha-Dystroglycan in Normal and Dystrophic Tissue. PLoS ONE, 2014, 9, e97567.	2.5	15
23	Regulator of G-Protein Signaling 5 Reduces HeyA8 Ovarian Cancer Cell Proliferation and Extends Survival in a Murine Tumor Model. Biochemistry Research International, 2012, 2012, 1-9.	3.3	9
24	Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy. Journal of Clinical Investigation, 2012, 122, 3330-3342.	8.2	57
25	Evidence for a role of dystroglycan regulating the membrane architecture of astroglial endfeet. European Journal of Neuroscience, 2011, 33, 2179-2186.	2.6	94
26	Rab3-interacting Molecule Î³ Isoforms Lacking the Rab3-binding Domain Induce Long Lasting Currents but Block Neurotransmitter Vesicle Anchoring in Voltage-dependent P/Q-type Ca2+ Channels. Journal of Biological Chemistry, 2010, 285, 21750-21767.	3.4	45
27	Inhibition of Recombinant N-Type CaV Channels by the Â2 Subunit Involves Unfolded Protein Response (UPR)-Dependent and UPR-Independent Mechanisms. Journal of Neuroscience, 2007, 27, 3317-3327.	3.6	26
28	Mutation Associated with an Autosomal Dominant Cone-Rod Dystrophy CORD7 Modifies RIM1-Mediated Modulation of Voltage-Dependent Ca²⁺Channels. Channels, 2007, 1, 144-147.	2.8	29
29	Fukutin-related Protein Associates with the Sarcolemmal Dystrophin-Glycoprotein Complex. Journal of Biological Chemistry, 2007, 282, 16713-16717.	3.4	36
30	RIM1 confers sustained activity and neurotransmitter vesicle anchoring to presynaptic Ca2+ channels. Nature Neuroscience, 2007, 10, 691-701.	14.8	212
31	ORL1 receptorâ€“mediated internalization of N-type calcium channels. Nature Neuroscience, 2006, 9, 31-40.	14.8	151
32	The CACNA1F Gene Encodes an L-Type Calcium Channel with Unique Biophysical Properties and Tissue Distribution. Journal of Neuroscience, 2004, 24, 1707-1718.	3.6	183
33	The Î±2Î´ Auxiliary Subunit Reduces Affinity of Ï‰-Conotoxins for Recombinant N-type (Cav2.2) Calcium Channels. Journal of Biological Chemistry, 2004, 279, 34705-34714.	3.4	74
34	Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nature Neuroscience, 2004, 7, 118-125.	14.8	128
35	Expression of T-type calcium channel splice variants in human glioma. Glia, 2004, 48, 112-119.	4.9	83
36	Modulation of High Voltage-Activated Calcium Channels by G Protein-Coupled Receptors. , 2004, , 331-367.		2

#	Article	IF	Citations
37	Expression of voltage-gated Ca2+ channel subtypes in cultured astrocytes. Glia, 2003, 41, 347-353.	4.9	119
38	Determinants of Inhibition of Transiently Expressed Voltage-gated Calcium Channels by Ï‰-Conotoxins GVIA and MVIIA. Journal of Biological Chemistry, 2003, 278, 20171-20178.	3.4	86
39	Synthesis and Evaluation of a New Class of Nifedipine Analogs with T-Type Calcium Channel Blocking Activity. Molecular Pharmacology, 2002, 61, 649-658.	2.3	88
40	Inhibition of transiently expressed low- and high-voltage-activated calcium channels by trivalent metal cations. Journal of Membrane Biology, 2002, 187, 225-238.	2.1	86
41	Molecular determinants of opioid analgesia: Modulation of presynaptic calcium channels. Drug Development Research, 2001, 54, 118-128.	2.9	9
42	G Protein Modulation of N-type Calcium Channels Is Facilitated by Physical Interactions between Syntaxin 1A and GÎ²Î³. Journal of Biological Chemistry, 2000, 275, 6388-6394.	3.4	126
43	Block of Voltage-Dependent Calcium Channels by Aliphatic Monoamines. Biophysical Journal, 2000, 79, 260-270.	0.5	24
44	Inhibition of subfornical organ neuronal potassium channels by vasopressin. Neuroscience, 1999, 93, 349-359.	2.3	29
45	Inhibiting Lactate Dehydrogenase A Enhances the Cytotoxicity of the Mitochondria Accumulating Antioxidant, Mitoquinone, in Melanoma Cells. , 0, , .		1